How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India?
Seven districts in Andhra Pradesh, South India. To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns (C&DST). Retros...
Gespeichert in:
| Veröffentlicht in: | PloS one 2011-10, Vol.6 (10), p.e25698-e25698 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e25698 |
|---|---|
| container_issue | 10 |
| container_start_page | e25698 |
| container_title | PloS one |
| container_volume | 6 |
| creator | Burugina Nagaraja, Sharath Satyanarayana, Srinath Chadha, Sarabjit Singh Kalemane, Santosha Jaju, Jyoti Achanta, Shanta Reddy, Kishore Potharaju, Vishnu Shamrao, Srinivas Rao Motta Dewan, Puneet Rony, Zachariah Tetali, Shailaja Anchala, Raghupathi Kannuri, Nanda Kishore Harries, Anthony David Singh, Sachdeva Kuldeep |
| description | Seven districts in Andhra Pradesh, South India.
To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns (C&DST).
Retrospective cohort study using routine programme data and Mycobacterium TB Culture C&DST between July 2008 and December 2009.
There were 202 individuals given a re-treatment regimen and included in the study. Overall treatment outcomes were: 68 (34%) with treatment success, 84 (42%) failed, 36 (18%) died, 13 (6.5%) defaulted and 1 transferred out. Treatment success for category I and II failures was low at 37%. In those with positive cultures, 81 had pan-sensitive strains with 31 (38%) showing treatment success, while 61 had drug-resistance strains with 9 (15%) showing treatment success. In 58 patients with negative cultures, 28 (48%) showed treatment success.
Treatment outcomes of patients who fail a first-line anti-TB treatment and who are not placed on an MDR-TB regimen are unacceptably poor. The worst outcomes are seen among category II failures and those with negative cultures or drug-resistance. There are important programmatic implications which need to be addressed. |
| doi_str_mv | 10.1371/journal.pone.0025698 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1309449637</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A476868867</galeid><doaj_id>oai_doaj_org_article_eb90992899c64d53aed8c3e71eaa3645</doaj_id><sourcerecordid>A476868867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c761t-b44bc8a222085ccb52427d8971ec707035396a548444277c29752c2415f759b43</originalsourceid><addsrcrecordid>eNqNk01v1DAQhiMEoqXwDxBYQgJxyOKvOPalqJSPrlRUqS1cLcdxdl1l7a3tUPj3eLtptUE9IB9szTzzznjsKYqXCM4QqdGHKz8Ep_rZ2jszgxBXTPBHxT4SBJcMQ_J457xXPIvxCsKKcMaeFnsYQ4wpIfvF9Ym_Aa0Ha5WscSmCm6UHnbI96GyIqeytM-DyE0jBqLTKBGiGdAupYIDzCax7pU0LvAPKge-fz8tMB7OwGc5CGbIOXPghLcHctVZ9fF486VQfzYtxPyh-fP1yeXxSnp59mx8fnZa6ZiiVDaWN5grnUnmldVNhiuuWixoZXcMakooIpirKKc2OWmNRV1hjiqqurkRDyUHxequ77n2UY7eiRAQKSgUjdSbmW6L16kqug12p8Ed6ZeWtwYeFVCFZ3RtpGgGFwFwIzWhbEWVaronJxShFGK2y1uGYbWhWptW5U0H1E9Gpx9mlXPhfkiCBUMWzwLtRIPjrwcQkVzZq0_fKGT9EKSBkhCEhMvnmH_Lhy43UQuX6ret8Tqs3mvKI1owzztmGmj1A5dWaldX5Z3U22ycB7ycBmUnmd1qoIUY5vzj_f_bs55R9u8MujerTMvp-SNa7OAXpFtTBxxhMd99jBOVmMO66ITeDIcfByGGvdt_nPuhuEshf7AMFXA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1309449637</pqid></control><display><type>article</type><title>How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India?</title><source>PubMed (Medline)</source><source>PLoS</source><source>MEDLINE</source><source>Full-Text Journals in Chemistry (Open access)</source><source>Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><creator>Burugina Nagaraja, Sharath ; Satyanarayana, Srinath ; Chadha, Sarabjit Singh ; Kalemane, Santosha ; Jaju, Jyoti ; Achanta, Shanta ; Reddy, Kishore ; Potharaju, Vishnu ; Shamrao, Srinivas Rao Motta ; Dewan, Puneet ; Rony, Zachariah ; Tetali, Shailaja ; Anchala, Raghupathi ; Kannuri, Nanda Kishore ; Harries, Anthony David ; Singh, Sachdeva Kuldeep</creator><creatorcontrib>Burugina Nagaraja, Sharath ; Satyanarayana, Srinath ; Chadha, Sarabjit Singh ; Kalemane, Santosha ; Jaju, Jyoti ; Achanta, Shanta ; Reddy, Kishore ; Potharaju, Vishnu ; Shamrao, Srinivas Rao Motta ; Dewan, Puneet ; Rony, Zachariah ; Tetali, Shailaja ; Anchala, Raghupathi ; Kannuri, Nanda Kishore ; Harries, Anthony David ; Singh, Sachdeva Kuldeep</creatorcontrib><description>Seven districts in Andhra Pradesh, South India.
To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns (C&DST).
Retrospective cohort study using routine programme data and Mycobacterium TB Culture C&DST between July 2008 and December 2009.
There were 202 individuals given a re-treatment regimen and included in the study. Overall treatment outcomes were: 68 (34%) with treatment success, 84 (42%) failed, 36 (18%) died, 13 (6.5%) defaulted and 1 transferred out. Treatment success for category I and II failures was low at 37%. In those with positive cultures, 81 had pan-sensitive strains with 31 (38%) showing treatment success, while 61 had drug-resistance strains with 9 (15%) showing treatment success. In 58 patients with negative cultures, 28 (48%) showed treatment success.
Treatment outcomes of patients who fail a first-line anti-TB treatment and who are not placed on an MDR-TB regimen are unacceptably poor. The worst outcomes are seen among category II failures and those with negative cultures or drug-resistance. There are important programmatic implications which need to be addressed.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0025698</identifier><identifier>PMID: 22022433</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Accreditation ; Adolescent ; Adult ; Aged ; Antitubercular Agents - therapeutic use ; Blister packs ; Care and treatment ; Chemotherapy ; Child ; Clinical outcomes ; Drug development ; Drug dosages ; Drug resistance ; Epidemiology ; Failure ; Health services ; Humans ; India ; Laboratories ; Lung diseases ; Medicine ; Microbial Sensitivity Tests ; Middle Aged ; Multidrug resistance ; Patient compliance ; Patients ; Population ; Public health ; Studies ; Treatment Failure ; Tuberculosis ; Tuberculosis, Multidrug-Resistant - drug therapy ; Young Adult</subject><ispartof>PloS one, 2011-10, Vol.6 (10), p.e25698-e25698</ispartof><rights>COPYRIGHT 2011 Public Library of Science</rights><rights>2011 Burugina Nagaraja et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Burugina Nagaraja et al. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c761t-b44bc8a222085ccb52427d8971ec707035396a548444277c29752c2415f759b43</citedby><cites>FETCH-LOGICAL-c761t-b44bc8a222085ccb52427d8971ec707035396a548444277c29752c2415f759b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191158/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191158/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22022433$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burugina Nagaraja, Sharath</creatorcontrib><creatorcontrib>Satyanarayana, Srinath</creatorcontrib><creatorcontrib>Chadha, Sarabjit Singh</creatorcontrib><creatorcontrib>Kalemane, Santosha</creatorcontrib><creatorcontrib>Jaju, Jyoti</creatorcontrib><creatorcontrib>Achanta, Shanta</creatorcontrib><creatorcontrib>Reddy, Kishore</creatorcontrib><creatorcontrib>Potharaju, Vishnu</creatorcontrib><creatorcontrib>Shamrao, Srinivas Rao Motta</creatorcontrib><creatorcontrib>Dewan, Puneet</creatorcontrib><creatorcontrib>Rony, Zachariah</creatorcontrib><creatorcontrib>Tetali, Shailaja</creatorcontrib><creatorcontrib>Anchala, Raghupathi</creatorcontrib><creatorcontrib>Kannuri, Nanda Kishore</creatorcontrib><creatorcontrib>Harries, Anthony David</creatorcontrib><creatorcontrib>Singh, Sachdeva Kuldeep</creatorcontrib><title>How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India?</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Seven districts in Andhra Pradesh, South India.
To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns (C&DST).
Retrospective cohort study using routine programme data and Mycobacterium TB Culture C&DST between July 2008 and December 2009.
There were 202 individuals given a re-treatment regimen and included in the study. Overall treatment outcomes were: 68 (34%) with treatment success, 84 (42%) failed, 36 (18%) died, 13 (6.5%) defaulted and 1 transferred out. Treatment success for category I and II failures was low at 37%. In those with positive cultures, 81 had pan-sensitive strains with 31 (38%) showing treatment success, while 61 had drug-resistance strains with 9 (15%) showing treatment success. In 58 patients with negative cultures, 28 (48%) showed treatment success.
Treatment outcomes of patients who fail a first-line anti-TB treatment and who are not placed on an MDR-TB regimen are unacceptably poor. The worst outcomes are seen among category II failures and those with negative cultures or drug-resistance. There are important programmatic implications which need to be addressed.</description><subject>Accreditation</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Blister packs</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Clinical outcomes</subject><subject>Drug development</subject><subject>Drug dosages</subject><subject>Drug resistance</subject><subject>Epidemiology</subject><subject>Failure</subject><subject>Health services</subject><subject>Humans</subject><subject>India</subject><subject>Laboratories</subject><subject>Lung diseases</subject><subject>Medicine</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Multidrug resistance</subject><subject>Patient compliance</subject><subject>Patients</subject><subject>Population</subject><subject>Public health</subject><subject>Studies</subject><subject>Treatment Failure</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk01v1DAQhiMEoqXwDxBYQgJxyOKvOPalqJSPrlRUqS1cLcdxdl1l7a3tUPj3eLtptUE9IB9szTzzznjsKYqXCM4QqdGHKz8Ep_rZ2jszgxBXTPBHxT4SBJcMQ_J457xXPIvxCsKKcMaeFnsYQ4wpIfvF9Ym_Aa0Ha5WscSmCm6UHnbI96GyIqeytM-DyE0jBqLTKBGiGdAupYIDzCax7pU0LvAPKge-fz8tMB7OwGc5CGbIOXPghLcHctVZ9fF486VQfzYtxPyh-fP1yeXxSnp59mx8fnZa6ZiiVDaWN5grnUnmldVNhiuuWixoZXcMakooIpirKKc2OWmNRV1hjiqqurkRDyUHxequ77n2UY7eiRAQKSgUjdSbmW6L16kqug12p8Ed6ZeWtwYeFVCFZ3RtpGgGFwFwIzWhbEWVaronJxShFGK2y1uGYbWhWptW5U0H1E9Gpx9mlXPhfkiCBUMWzwLtRIPjrwcQkVzZq0_fKGT9EKSBkhCEhMvnmH_Lhy43UQuX6ret8Tqs3mvKI1owzztmGmj1A5dWaldX5Z3U22ycB7ycBmUnmd1qoIUY5vzj_f_bs55R9u8MujerTMvp-SNa7OAXpFtTBxxhMd99jBOVmMO66ITeDIcfByGGvdt_nPuhuEshf7AMFXA</recordid><startdate>20111011</startdate><enddate>20111011</enddate><creator>Burugina Nagaraja, Sharath</creator><creator>Satyanarayana, Srinath</creator><creator>Chadha, Sarabjit Singh</creator><creator>Kalemane, Santosha</creator><creator>Jaju, Jyoti</creator><creator>Achanta, Shanta</creator><creator>Reddy, Kishore</creator><creator>Potharaju, Vishnu</creator><creator>Shamrao, Srinivas Rao Motta</creator><creator>Dewan, Puneet</creator><creator>Rony, Zachariah</creator><creator>Tetali, Shailaja</creator><creator>Anchala, Raghupathi</creator><creator>Kannuri, Nanda Kishore</creator><creator>Harries, Anthony David</creator><creator>Singh, Sachdeva Kuldeep</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20111011</creationdate><title>How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India?</title><author>Burugina Nagaraja, Sharath ; Satyanarayana, Srinath ; Chadha, Sarabjit Singh ; Kalemane, Santosha ; Jaju, Jyoti ; Achanta, Shanta ; Reddy, Kishore ; Potharaju, Vishnu ; Shamrao, Srinivas Rao Motta ; Dewan, Puneet ; Rony, Zachariah ; Tetali, Shailaja ; Anchala, Raghupathi ; Kannuri, Nanda Kishore ; Harries, Anthony David ; Singh, Sachdeva Kuldeep</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c761t-b44bc8a222085ccb52427d8971ec707035396a548444277c29752c2415f759b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Accreditation</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Blister packs</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Clinical outcomes</topic><topic>Drug development</topic><topic>Drug dosages</topic><topic>Drug resistance</topic><topic>Epidemiology</topic><topic>Failure</topic><topic>Health services</topic><topic>Humans</topic><topic>India</topic><topic>Laboratories</topic><topic>Lung diseases</topic><topic>Medicine</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Multidrug resistance</topic><topic>Patient compliance</topic><topic>Patients</topic><topic>Population</topic><topic>Public health</topic><topic>Studies</topic><topic>Treatment Failure</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burugina Nagaraja, Sharath</creatorcontrib><creatorcontrib>Satyanarayana, Srinath</creatorcontrib><creatorcontrib>Chadha, Sarabjit Singh</creatorcontrib><creatorcontrib>Kalemane, Santosha</creatorcontrib><creatorcontrib>Jaju, Jyoti</creatorcontrib><creatorcontrib>Achanta, Shanta</creatorcontrib><creatorcontrib>Reddy, Kishore</creatorcontrib><creatorcontrib>Potharaju, Vishnu</creatorcontrib><creatorcontrib>Shamrao, Srinivas Rao Motta</creatorcontrib><creatorcontrib>Dewan, Puneet</creatorcontrib><creatorcontrib>Rony, Zachariah</creatorcontrib><creatorcontrib>Tetali, Shailaja</creatorcontrib><creatorcontrib>Anchala, Raghupathi</creatorcontrib><creatorcontrib>Kannuri, Nanda Kishore</creatorcontrib><creatorcontrib>Harries, Anthony David</creatorcontrib><creatorcontrib>Singh, Sachdeva Kuldeep</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints Resource Center</collection><collection>Science In Context</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>https://resources.nclive.org/materials</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest advanced technologies & aerospace journals</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burugina Nagaraja, Sharath</au><au>Satyanarayana, Srinath</au><au>Chadha, Sarabjit Singh</au><au>Kalemane, Santosha</au><au>Jaju, Jyoti</au><au>Achanta, Shanta</au><au>Reddy, Kishore</au><au>Potharaju, Vishnu</au><au>Shamrao, Srinivas Rao Motta</au><au>Dewan, Puneet</au><au>Rony, Zachariah</au><au>Tetali, Shailaja</au><au>Anchala, Raghupathi</au><au>Kannuri, Nanda Kishore</au><au>Harries, Anthony David</au><au>Singh, Sachdeva Kuldeep</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India?</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2011-10-11</date><risdate>2011</risdate><volume>6</volume><issue>10</issue><spage>e25698</spage><epage>e25698</epage><pages>e25698-e25698</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Seven districts in Andhra Pradesh, South India.
To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns (C&DST).
Retrospective cohort study using routine programme data and Mycobacterium TB Culture C&DST between July 2008 and December 2009.
There were 202 individuals given a re-treatment regimen and included in the study. Overall treatment outcomes were: 68 (34%) with treatment success, 84 (42%) failed, 36 (18%) died, 13 (6.5%) defaulted and 1 transferred out. Treatment success for category I and II failures was low at 37%. In those with positive cultures, 81 had pan-sensitive strains with 31 (38%) showing treatment success, while 61 had drug-resistance strains with 9 (15%) showing treatment success. In 58 patients with negative cultures, 28 (48%) showed treatment success.
Treatment outcomes of patients who fail a first-line anti-TB treatment and who are not placed on an MDR-TB regimen are unacceptably poor. The worst outcomes are seen among category II failures and those with negative cultures or drug-resistance. There are important programmatic implications which need to be addressed.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>22022433</pmid><doi>10.1371/journal.pone.0025698</doi><tpages>e25698</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2011-10, Vol.6 (10), p.e25698-e25698 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1309449637 |
| source | PubMed (Medline); PLoS; MEDLINE; Full-Text Journals in Chemistry (Open access); Directory of Open Access Journals; EZB Electronic Journals Library |
| subjects | Accreditation Adolescent Adult Aged Antitubercular Agents - therapeutic use Blister packs Care and treatment Chemotherapy Child Clinical outcomes Drug development Drug dosages Drug resistance Epidemiology Failure Health services Humans India Laboratories Lung diseases Medicine Microbial Sensitivity Tests Middle Aged Multidrug resistance Patient compliance Patients Population Public health Studies Treatment Failure Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Young Adult |
| title | How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T19%3A29%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20do%20patients%20who%20fail%20first-line%20TB%20treatment%20but%20who%20are%20not%20placed%20on%20an%20MDR-TB%20regimen%20fare%20in%20South%20India?&rft.jtitle=PloS%20one&rft.au=Burugina%20Nagaraja,%20Sharath&rft.date=2011-10-11&rft.volume=6&rft.issue=10&rft.spage=e25698&rft.epage=e25698&rft.pages=e25698-e25698&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0025698&rft_dat=%3Cgale_plos_%3EA476868867%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1309449637&rft_id=info:pmid/22022433&rft_galeid=A476868867&rft_doaj_id=oai_doaj_org_article_eb90992899c64d53aed8c3e71eaa3645&rfr_iscdi=true |